Academic interests
- Economic evaluation of health care interventions
- Decision-analytic modeling
- Screening for cervical cancer
Courses taught
- HEVAL4200 – Fundamentals of economic evaluation
Background
- M.Phil. in Health Economics, Policy and Management, University of Oslo, 2014
- BA in Economics, University of Oslo, 2012
- BA in Health Management and Health Economics, University of Oslo, 2011
Awards
- The Society for Medical Decision Making’s Lee B. Lusted Student Prize in Health Services and Policy Research
Partners
- Department of Biostatistics, University of Aarhus, Denmark
- The Cancer Registry of Norway
- Department of clinical pathology, University Hospital of North Norway
- Center for Health Decision Science, Harvard T. H. Chan School of Public Health
Publications
-
-
-
Løyland, Hanna Isabel; Pedersen, Kine; Sten Gahmberg, Susanna; Gaarder Harsheim, Ingrid; Sæther, Erik Magnus & Iversen, Tor
[Show all 8 contributors for this article]
(2023).
Effekter, gevinster og kostnader ved digital hjemmeoppfølging–en samfunnsøkonomisk analyse basert på et pragmatisk randomisert forsøk.
Magma forskning og viten.
ISSN 1500-0788.
26(5),
p. 124–135.
doi:
10.23865/magma.v26.1426.
Full text in Research Archive
Show summary
Denne studien omhandler en utprøving av digital hjemmeoppfølging i helsetjenesten og omfatter seks lokale prosjekter i kommunene Stad, Bodø, Larvik, Oslo (med bydelene Sagene, Grünerløkka, Gamle Oslo og St. Hanshaugen), Ullensaker (i samarbeid med Gjerdrum) og Kristiansand (i samarbeid med flere Agder-kommuner). Utprøvingen ble gjennomført som en pragmatisk randomisert kontrollert studie. Målgruppen var personer med kroniske sykdommer, med middels til høy risiko for forverret helsetilstand, reinnleggelse på sykehus eller økt behov for helse-og omsorgstjenester. Pasientene i tiltaksgruppen fikk utarbeidet en egenbehandlingsplan, utførte selv avtalte målinger og svarte på spørsmål om sin helsetilstand på et nettbrett. Pasientene kunne følge med på egne resultater. I tillegg tok en sykepleier i oppfølgingstjenesten kontakt dersom målingene var utenfor pasientens normalverdier, for å avklare behov for helsejhelp. Samlet sett viser vår analyse at verdien
av de prissatte nyttevirkningene av
tiltaket (bedre helserelatert livskvalitet
og endret ressursbruk i helsetjenesten) er
lavere enn kostnadene ved å tilby digital
hjemmeoppfølging. Tiltaket gir imidlertid
også virkninger som det ikke har vært
mulig å prissette. Vi finner at digital
hjemmeoppfølging
bidrar til at pasientene
får økt forståelse og mestring av egen
sykdom, og derigjennom føler seg tryggere
og er mer fornøyd med oppfølging av
egen helse. Fremover vil det være viktig å
begrense ressursbruken i helsetjenesten,
samtidig som man retter tilbudet mot personer
som har særlig nytte av det. Dette
innebærer at de som får digital hjemmeoppfølging,
hverken må være for syke til
at det er for sent å forebygge forverring
og økt bruk av helsetjenester, eller for
friske til å dra nytte av tjenesten. Brukt
riktig kan digital hjemmeoppfølging være
et godt verktøy i tilbudet til pasienter med
kroniske sykdommer og særlige behov.
-
Pedersen, Kine; Løyland, Hanna Isabel; Erik Magnus, Sæther; Sten Gahmberg, Susanna; Abelsen, Birgit & Snilsberg, Øyvind
[Show all 7 contributors for this article]
(2023).
Primærhelseteam – en mer teambasert fastlegetjeneste.
Magma forskning og viten.
ISSN 1500-0788.
26(5),
p. 73–83.
doi:
10.23865/magma.v26.1421.
Full text in Research Archive
Show summary
Primærhelseteam (PHT) er en ny arbeidsform i fastlegetjenesten der lege, sykepleier og helsesekretær jobber sammen i team. Teamet skal tilby gode tjenester og arbeide systematisk med pasientsikkerhet og kvalitetsforbedring. Målgruppene for primærhelseteam er listeinnbyggere med kronisk sykdom, psykiske lidelser og rusavhengighet, skrøpelige eldre, og brukere med
utviklingshemming og funksjonsnedsettelser.
Et nasjonalt forsøk med primærhelseteam startet i 2018.
Forsøket følges av en evaluering. I denne artikkelen forsøker vi å svare på spørsmålene: Hvordan jobber legekontorene
i PHT-forsøket som team, og hvilke effekter gir det? Videre belyser vi hvordan funnene kan brukes i utformingen
av en mer teambasert fastlegetjeneste. Vi bygger på datainnsamlingen og hovedfunnene fra evalueringen av PHT,
og utdyper tolkningen av funnene i lys av internasjonal litteratur. Vi finner at personellet på legekontorene
opplever at teamarbeid gir gode resultater – både for pasientene og for dem selv i form av økt arbeidstrivsel.
Teameffektiviteten på legekontorene avhenger av struktur (som møter, maler og prosedyrer) og felles arbeidsmåter,
kontinuitet i personellgruppen, grad av engasjement for teamarbeid samt tydelig ledelse av og fastlegenes individuelle tilfredshet med teamarbeidet. Vi finner
at PHT-sykepleierne i større grad har bidratt til bedre oppfølging av pasienter i målgruppene enn til å avlaste fastlegen. Resultatet samsvarer med effektmålene
for forsøket, der vekten er lagt på kvalitetsforbedring
og ikke produktivitetsforbedring på fastlegekontoret.
Evalueringen viser at det er ressurs- og
tidkrevende å utvikle teamarbeid. For å lykkes med en eventuell videre implementering av en tverrfaglig, teambasert
fastlegeordning, må det være en klar interesse for dette blant fastlegene.
-
-
-
Knauss, Tara; Hansen, Bo Lars Thorvald Terning; Pedersen, Kine; Aasbø, Gunvor; Kunst, Natalia & Burger, Emily Annika
(2022).
The cost-effectiveness of opt-in and send-to-all HPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: The Equalscreen randomized controlled trial.
Gynecologic Oncology.
ISSN 0090-8258.
168,
p. 39–47.
doi:
10.1016/j.ygyno.2022.10.027.
-
Portnoy, Allison; Pedersen, Kine; Nygård, Mari; Trogstad, Lill; Kim, Jane J. & Burger, Emily Annika
(2022).
Identifying a Single Optimal Integrated Cervical Cancer Prevention Policy in Norway: A Cost-Effectiveness Analysis.
Medical decision making.
ISSN 0272-989X.
42(6),
p. 795–807.
doi:
10.1177/0272989X221082683.
-
Cyr, Pascale Renée; Pedersen, Kine; Iyer, Anita Lakshmi; Bundorf, Kate; Goldhaber-Fiebert, Jeremy & Gyrd-Hansen, Dorte
[Show all 8 contributors for this article]
(2021).
Providing more balanced information on the harms and benefits of cervical cancer screening: A randomized survey among US and Norwegian women.
Preventive Medicine Reports.
ISSN 2211-3355.
doi:
10.1016/j.pmedr.2021.101452.
Full text in Research Archive
Show summary
We aimed to identify how additional information about benefits and harms of cervical cancer (CC) screening impacted intention to participate in screening, what type of information on harms women preferred receiving, from whom, and whether it differed between two national healthcare settings. We conducted a survey that randomized screen-eligible women in the United States (n = 1084) and Norway (n = 1060) into four groups according to the timing of introducing additional information. We found that additional information did not significantly impact stated intentions-to-participate in screening or follow-up testing in either country; however, the proportion of Norwegian women stating uncertainty about seeking precancer treatment increased from 7.9% to 14.3% (p = 0.012). Women reported strong system-specific preferences for sources of information: Norwegians (59%) preferred it come from a national public health agency while Americans (59%) preferred it come from a specialist care provider. Regression models revealed having a prior Pap-test was the most important predictor of intentions-to-participate in both countries, while having lower income reduced the probabilities of intentions-to-follow-up and seek precancer treatment among U.S. women. These results suggest that additional information on harms is unlikely to reduce participation in CC screening but could increase decision uncertainty to seek treatment. Providing unbiased information would improve on the ethical principle of respect for autonomy and self-determination. However, the clinical impact of additional information on women's understanding of the trade-offs involved with CC screening should be investigated. Future studies should also consider country-specific socioeconomic barriers to screening if communication re-design initiatives aim to improve CC screening participation.
-
Pedersen, Kine; Portnoy, Allison; Sy, Stephen; Hansen, Bo T.; Trope, Ameli & Kim, Jane J.
[Show all 7 contributors for this article]
(2021).
Switching clinic-based cervical cancer screening programs to human papillomavirus self-sampling: A cost-effectiveness analysis of vaccinated and unvaccinated Norwegian women.
International Journal of Cancer.
ISSN 0020-7136.
doi:
10.1002/ijc.33850.
Full text in Research Archive
Show summary
Several countries have implemented primary human papillomavirus (HPV) testing for
cervical cancer screening. HPV testing enables home-based, self-collected sampling
(self-sampling), which provides similar diagnostic accuracy as clinician-collected samples. We evaluated the impact and cost-effectiveness of switching an entire organized screening program to primary HPV self-sampling among cohorts of HPV
vaccinated and unvaccinated Norwegian women. We conducted a model-based
analysis to project long-term health and economic outcomes for birth cohorts with
different HPV vaccine exposure, that is, preadolescent vaccination (2000- and
2008-cohorts), multiage cohort vaccination (1991-cohort) or no vaccination (1985-
cohort). We compared the cost-effectiveness of switching current guidelines with
clinician-collected HPV testing to HPV self-sampling for these cohorts and considered
an additional 44 strategies involving either HPV self-sampling or clinician-collected
HPV testing at different screening frequencies for the 2000- and 2008-cohorts. Given
Norwegian benchmarks for cost-effectiveness, we considered a strategy with an additional cost per quality-adjusted life-year below $55 000 as cost-effective. HPV selfsampling strategies considerably reduced screening costs (ie, by 24%-40% across
cohorts and alternative strategies) and were more cost-effective than cliniciancollected HPV testing. For cohorts offered preadolescent vaccination, cost-effective
strategies involved HPV self-sampling three times (2000-cohort) and twice
(2008-cohort) per lifetime. In conclusion, we found that switching from cliniciancollected to self-collected HPV testing in cervical screening may be cost-effective
among both highly vaccinated and unvaccinated cohorts of Norwegian women.
-
Portnoy, Allison; Pedersen, Kine; Trogstad, Lill; Hansen, Bo Terning; Feiring, Berit & Laake, Ida
[Show all 11 contributors for this article]
(2021).
Impact and cost-effectiveness of strategies to accelerate cervical cancer elimination: A model-based analysis.
Preventive Medicine.
ISSN 0091-7435.
144.
doi:
10.1016/j.ypmed.2020.106276.
Full text in Research Archive
Show summary
Following the global call for action by the World Health Organization to eliminate cervical cancer (CC), we evaluated how each CC policy decision in Norway influenced the timing of CC elimination, and whether introducing nonavalent human papillomavirus (HPV) vaccine would accelerate elimination timing and be cost-effective. We used a multi-modeling approach that captured HPV transmission and cervical carcinogenesis to estimate the CC incidence associated with six past and future CC prevention policy decisions compared with a pre-vaccination scenario involving 3-yearly cytology-based screening. Scenarios examined the introduction of routine HPV vaccination of 12-year-old girls with quadrivalent vaccine in 2009, a temporary catch-up program for females aged up to 26 years in 2016–2018 with bivalent vaccine, the universal switch to bivalent vaccine in 2017, expansion to include 12-year-old boys in 2018, the switch from cytology- to HPV-based screening for women aged 34–69 in 2020, and the potential switch to nonavalent vaccine in 2021. Introducing routine female vaccination in 2009 enabled elimination to be achieved by 2056 and prevented 17,300 cases. Cumulatively, subsequent policy decisions accelerated elimination to 2039. According to our modeling assumptions, switching to the nonavalent vaccine would not be considered ‘good value for money’ at relevant cost-effectiveness thresholds in Norway unless the incremental cost was $19 per dose or less (range: $17–24) compared to the bivalent vaccine. CC control policies implemented over the last decade in Norway may have accelerated the timeframe to elimination by more than 17 years and prevented over 23,800 cases by 2110.
-
-
-
-
-
-
Burger, Emily; Pedersen, Kine; Sy, Stephen; Kristiansen, Ivar Sønbø & Kim, Jane J
(2017).
Choosing wisely: a model-based analysis evaluating the trade-offs in cancer benefit and diagnostic referrals among alternative HPV testing strategies in Norway.
British Journal of Cancer.
ISSN 0007-0920.
117(6),
p. 783–790.
doi:
10.1038/bjc.2017.248.
Full text in Research Archive
-
-
Pedersen, Kine; Sørbye, Sveinung Wergeland; Kristiansen, Ivar Sønbø & Burger, Emily
(2017).
Using novel biomarkers to triage young adult women with minor cervical lesions: a cost-effectiveness analysis.
BJOG: An International Journal of Obstetrics and Gynaecology.
ISSN 1470-0328.
124(3),
p. 474–484.
doi:
10.1111/1471-0528.14135.
Show summary
Objective
To evaluate the short-term consequences and cost-effectiveness associated with the use of novel biomarkers to triage young adult women with minor cervical cytological lesions.
Design
Model-based economic evaluation using primary epidemiological data from Norway, supplemented with data from European and American clinical trials.
Setting
Organised cervical cancer screening in Norway.
Population
Women aged 25–33 years with minor cervical cytological lesions detected at their primary screening test.
Methods
We expanded an existing simulation model to compare 12 triage strategies involving alternative biomarkers (i.e. reflex human papillomavirus (HPV) DNA/mRNA testing, genotyping, and dual staining) with the current Norwegian triage guidelines.
Main outcome measures
The number of high-grade precancers detected and resource use (e.g. monetary costs and colposcopy referrals) for a single screening round (3 years) for each triage strategy. Cost-efficiency, defined as the additional cost per additional precancer detected of each strategy compared with the next most costly strategy.
Results
Five strategies were identified as cost-efficient, and are projected to increase the precancer detection rate between 18 and 57%, compared with current guidelines; however, the strategies did not uniformly require additional resources. Strategies involving HPV mRNA testing required fewer resources, whereas HPV DNA-based strategies detected >50% more precancers, but were more costly and required twice as many colposcopy referrals compared with the current guidelines.
Conclusion
Strategies involving biomarkers to triage younger women with minor cervical cytological lesions have the potential to detect additional precancers, yet the optimal strategy depends on the resources available as well as decision-makers' and women's acceptance of additional screening procedures.
-
Melberg, Hans Olav; Olsen, Camilla Beck & Pedersen, Kine
(2016).
Did hospitals respond to changes in weights of Diagnosis Related Groups in Norway between 2006 and 2013?
Health Policy.
ISSN 0168-8510.
120(9),
p. 992–1000.
doi:
10.1016/j.healthpol.2016.07.013.
Show summary
Abstract
It has been argued that activity based payment systems make hospitals focus on the diagnostic groups that are most beneficial given costs and reimbursement rates. This article tests this hypothesis by exploring the relationship between changes in the reimbursement rates and changes in the number of registered treatment episodes for all diagnosis-related groups in Norway between 2006 and 2013. The number of treatment episodes can be affected by many factors and in order to isolate the effect of changes in the reimbursement system, we exclude DRGs affected by policy reforms and administrative changes. The results show that hospitals increased the number of admissions in a specific DRG four times more when the reimbursement was increased, relative to the change for DRGs with reduced rates. The direction of the result was consistent across time periods and sub-groups such as surgical vs. medical, and inpatient vs. outpatient DRGs. The effect was smaller, but remained significant after eliminating DRGs that were most likely to be affected by upcoding. Activities that the hospital had little control over, such as the number of births, had small effects, while activity levels in more discretionary categories, for instance mental diseases, were more affected. This demonstrates that contrary to the wishes of policy makers the economic incentives affect hospital reporting and priority setting behavior.
-
Pedersen, Kine; Burger, Emily; Sy, Stephen; Kristiansen, Ivar Sønbø & Kim, Jane J.
(2016).
Cost-effective management of women with minor cervical lesions: Revisiting the application of HPV DNA testing.
Gynecologic Oncology.
ISSN 0090-8258.
143(2),
p. 326–333.
doi:
10.1016/j.ygyno.2016.08.231.
Full text in Research Archive
Show summary
Background
Lack of consensus in management guidelines for women with minor cervical lesions, coupled with novel screening approaches, such as human papillomavirus (HPV) genotyping, necessitate revisiting prevention policies. We evaluated the cost-effectiveness and resource trade-offs of alternative triage strategies to inform cervical cancer prevention in Norway.
Methods
We used a decision-analytic model to compare the lifetime health and economic consequences associated with ten novel candidate approaches to triage women with minor cervical lesions. Candidate strategies varied by: 1) the triage test(s): HPV testing in combination with cytology, HPV testing alone with or without genotyping for HPV-16 and -18, and immediate colposcopy, and 2) the length of time between index and triage testing (i.e., 6, 12 or 18 months). Model outcomes included quality-adjusted life-years (QALYs), lifetime societal costs, and resource use (e.g., colposcopy referrals).
Results
The current Norwegian guidelines were less effective and more costly than candidate strategies. Given a commonly-cited willingness-to-pay threshold in Norway of $100,000 per QALY gained, the preferred strategy involved HPV genotyping with immediate colposcopy referral for HPV-16 or -18 positive and repeat HPV testing at 12 months for non-HPV-16 or -18 positive ($78,010 per QALY gained). Differences in health benefits among candidate strategies were small, while resource use varied substantially. More effective strategies required a moderate increase in colposcopy referrals (e.g., a 9% increase for the preferred strategy) compared with current levels.
Conclusion
New applications of HPV testing may improve management of women with minor cervical lesions, yet are accompanied by a trade-off of increased follow-up procedures.
-
Pedersen, Kine; Sørbye, Sveinung Wergeland; Burger, Emily; Lönnberg, Stefan & Kristiansen, Ivar Sønbø
(2015).
Using decision-analytic modeling to isolate interventions that are feasible, efficient and optimal: an application from the Norwegian Cervical Cancer Screening Program.
Value in Health.
ISSN 1098-3015.
18(8),
p. 1088–1097.
doi:
10.1016/j.jval.2015.08.003.
Full text in Research Archive
-
Pedersen, Kine; Lönnberg, Stefan; Skare, Gry Baadstrand; Sørbye, Sveinung Wergeland; Burger, Emily & Kristiansen, Ivar Sønbø
(2015).
Kostnader ved Masseundersøkelsen mot livmorhalskreft.
Sykepleien Forskning.
ISSN 1890-2936.
p. 62–71.
doi:
10.4220/Sykepleienf.2015.53414.
Full text in Research Archive
View all works in Cristin
-
-
Burger, Emily; Pedersen, Kine; Sy, Stephen; Kristiansen, Ivar Sønbø & Kim, Jane J.
(2017).
Primary HPV-based Cervical Cancer Screening: Balancing Health Benefits Colposcopy Referrals.
-
Pedersen, Kine; Burger, Emily; Sy, Stephen; Kristiansen, Ivar Sønbø & Kim, Jane J.
(2016).
Cost-effective management of women with minor cervical lesions: Revisiting the application of HPV DNA testing.
-
Pedersen, Kine; Sørbye, Sveinung Wergeland; Kristiansen, Ivar Sønbø & Burger, Emily
(2015).
Novel Biomarkers to Triage Women with Minor Cervical Lesions: Quantifying the Cost-Effectiveness Tradeoffs to Ensure Feasible Implementation.
-
Pedersen, Kine; Burger, Emily; Campbell, Suzanne; Nygård, Mari & Lönnberg, Stefan
(2015).
Risk of cervical cancer by screening intensity: A registry-based analysis.
-
Pedersen, Kine; Sørbye, Sveinung Wergeland; Burger, Emily; Lönnberg, Stefan & Kristiansen, Ivar Sønbø
(2015).
Quantifying benefits and harms in cervical cancer screening: A decision analytic approach.
-
Pedersen, Kine
(2015).
Kostnad-nytte-avveininger i screening mot livmorhalskreft.
Tidsskrift for Den norske legeforening.
ISSN 0029-2001.
135(11),
p. 1022–1023.
doi:
10.4045/tidsskr.15.0468.
-
Pedersen, Kine; Sørbye, Sveinung Wergeland; Lönnberg, Stefan; Burger, Emily & Kristiansen, Ivar Sønbø
(2014).
Trade-offs in cervial cancer screening - Balancing detected cancer precursors and resource use.
Show summary
Reflex HPV-testing allows for improvements in both effectiveness and cost-effectiveness of the current screening algorithm. Candidate strategies can detect a larger number of precancers while using fewer resources compared to current practice; however, the optimal strategy depends on society’s willingness to pay costs and accept harms. Ultimately, the down-stream effectiveness of the alternative algorithms will depend on the extent to which precancers regress or progress into cancer.
-
-
Groeneveld, linn; Engesæter, Birgit; Aasbø, Gunvor; Hansen, Mona; Christiansen, Irene Kraus & Berland, Jannicke
[Show all 14 contributors for this article]
(2021).
Prosjektforslag hjemmetest: Implementering av hjemmeprøvetaking i Livmorhalsprogrammet.
Kreftregisteret - Institutt for populasjonsbasert kreftforskning.
Full text in Research Archive
Show summary
Effektiv forebygging av livmorhalskreft fordrer at kvinner deltar i Livmorhalsprogrammet som anbefalt. I dag er deltakelsen på 71%, mens anbefalt deltakelse er minimum 80% ifølge internasjonale retningslinjer. Over halvparten av livmorhalskrefttilfellene diagnostisert i Norge er blant kvinner som ikke har tatt livmorhalsprøver som anbefalt. I tillegg får de som aldri eller sjelden screener seg, oftere påvist livmorhalskreft på et høyere stadium enn de som screener seg som anbefalt. En ny norsk studie viser at tilbud om hjemmetest til denne gruppen avdekker et betydelig antall forstadier til kreft og kreft som ikke ville blitt avdekket ved ordinær påminnelse om å ta screeningprøve hos lege. Både internasjonale og norske studier har vist at man på en kostnadseffektiv måte kan oppnå en betydelig forbedret deltakelse i screeningprogrammet blant kvinner dersom de får tilbud om hjemme-prøvetaking
(= hjemmetest). Helsedirektoratet har bedt Kreftregisteret om å utrede hjemmetest som et tiltak for å øke deltakelsen
i Livmorhalsprogrammet blant kvinner som ikke har møtt til screening på mer enn ti år. Forslaget skulle også
inkludere bruk av hjemmetest for kvinner som ikke har tatt livmorhalsprøve på grunn av covid-19 pandemien, og
eventuelle andre grupper.
Denne rapporten skisserer hvordan hjemmetest kan innføres i Livmorhalsprogrammet. Anbefalt strategi er å gi
tilbud om hjemmetest til tre grupper. Den første gruppen er kvinner med betydelig økt risiko for alvorlige celleforandringer
i livmorhalsen på grunn av manglende deltakelse over lengre tid. Spesifikt anbefales det at kvinner uten
registrert livmorhalsprøve i løpet av ti år eller mer får hjemmetest tilsendt i posten (opt-out). Den andre gruppen er
kvinner uten registrert livmorhalsprøve de siste åtte eller ni år, denne gruppen anbefales å få mulighet til å bestille
hjemmetest (opt-in). Den siste gruppen er kvinner som av fysiske eller psykiske årsaker vegrer seg for å ta en
livmorhalsprøve hos legen. Det planlegges at disse kvinnene får tilbud om hjemmetest via lege. Hjemmetesting er
enda mer aktuelt nå på grunn av covid-19 pandemien. Normalt registrerer Livmorhalsprogrammet cirka 450 000
prøver per år. Grove estimater viser at det ble registrert 50 000 færre livmorhalsprøver enn forventet i 2020. En
ny smittebølge av covid-19 i november 2020, som førte til en ny sosial nedstenging av samfunnet i Oslo-regionen i
januar 2021, ser også ut til å ha påvirket antall registrerte prøver i januar 2021.
Hjemmetest i seg selv er et mer kostnadseffektivt alternativ enn legetatt prøve, ettersom helsepersonell ikke
involveres i selve prøvetakingen. De helseøkonomiske modellene inkludert i rapporten viser at tilbud om hjemmetest
gir en helsegevinst ved at andelen kvinner som deltar i screeningprogrammet vil øke, og dermed reduseres deres
livstidsrisiko for å utvikle livmorhalskreft. Økt deltakelse vil imidlertid medføre en økt kostnad for screeningvirksomheten, men for samfunnet som en helhet vil det være lønnsomt. Dette tilbudet vil resultere i samfunnsmessige besparelser fordi færre kvinner vil måtte behandles for livmorhalskreft. Kvinner som rammes av livmorhalskreft
får økte kvalitetsjusterte leveår (på engelsk: quality-adjusted life years -QALYs). I vår forenklede modell-baserte
analyse ble det estimert at opt-out hjemmetesting, sammenlignet med påminnelsesbrev, kunne gi mer enn 1 365
ekstra (diskontert) QALYs blant de 217 000 kvinnene som kvalifiserer til hjemmetest i løpet av fem år. Dette er
langt flere QALYs enn de 155 som behøves for å være kostnadseffektiv, gitt at myndighetenes betalingsvillighet for
et ekstra leveår er 385 000 kroner. Samlet viser også beregningsmodellene som er gjennomført, at kostnaden per
tilfelle av alvorlige celleforandringer som oppdages, er lavere ved hjemmetest sammenlignet med vanlig påminnelse
og prøvetaking hos lege.
-
Abelsen, Birgit; Gaski, Margrete; Godager, Geir; Løyland, Hanna Isabel; Pedersen, Kine & Snilsberg, Øyvind
[Show all 9 contributors for this article]
(2019).
Evaluering av pilotprosjekt med primærhelseteam og alternative finansieringsordninger. Statusrapport II.
Helsedirektoratet.
-
View all works in Cristin
Published
Mar. 25, 2015 10:09 AM
- Last modified
Mar. 25, 2015 10:34 AM